Article
How America Took Out The Nord Stream Pipeline
aboutLiberty Portal
Liberty Portal is your gateway for free markets and free thinking. We aggregate open-sourced content to promote and popularize important people and lessons within the liberty movement.
suggested
Apr 24, 2026 / Tyler Durden
FDA Approves First Gene Therapy To Treat Deafness
FDA Approves First Gene Therapy To Treat Deafness
Authored by Zachary Stieber via The Epoch Times (emphasis ours),
Federal regulators on Thursday approved the first gene therapy to restore hearing, just two months after the therapy’s maker formally requested a license.
Dr. Marty Makary, the Food and Drug Administration's commissioner, in an undated file photograph. Madalina Vasiliu/The Epoch Times
The Food and Drug Administration approved the Regeneron therapy, Otarmeni, for children and adults with severe or profound hearing loss associated with OTOF gene variants.
The approval came 61 days after Regeneron filed for a...
Read more
May 15, 2026 / Tyler Durden
Closing Arguments In High-Stakes OpenAI Trial Focus On Reputation, Character
Closing Arguments In High-Stakes OpenAI Trial Focus On Reputation, Character
Authored by Beige Luciano-Adams via The Epoch Times (emphasis ours),
OAKLAND, Calif.—After nearly three weeks of presented evidence, an Oakland jury on May 14 heard final arguments in a high-stakes legal battle that could have profound impacts on the race for artificial intelligence.
In a courtroom sketch, Sam Altman listens as OpenAI President Greg Brockman testifies during Elon Musk's lawsuit trial over OpenAI's for-profit conversion, at a federal courthouse in Oakland, Calif., on May 4, 2026. Vicki Behringer/Reuters
Tech moguls Elon Musk and...
Read more
Mar 11, 2026 / Connor O'Keeffe
Launching a War on Iran Was No Act of Courage
As recent history shows, there are few things more courageous for a president to do than face down the ever-accelerating, wealth-draining, conflict-amplifying warfare state in DC. Trump has decided to go in the opposite direction.
Read more




